array(13) { ["code"]=> string(2) "es" ["id"]=> string(1) "2" ["native_name"]=> string(8) "Español" ["major"]=> string(1) "1" ["active"]=> string(1) "1" ["default_locale"]=> string(5) "es_ES" ["encode_url"]=> string(1) "0" ["tag"]=> string(5) "es-es" ["missing"]=> int(0) ["translated_name"]=> string(8) "Español" ["url"]=> string(174) "https://www.prosigna.com/es/resource/comparison-of-pam50-risk-of-recurrence-score-with-oncotype-dx-and-ihc4-for-predicting-risk-of-distant-recurrence-after-endocrine-therapy/" ["country_flag_url"]=> string(87) "https://www.prosigna.com/wp-content/plugins/sitepress-multilingual-cms/res/flags/es.png" ["language_code"]=> string(2) "es" } native: Español
translated: Español
IN the US OUTSIDE the US
CONTACTO

Contacte con nosotros
Lunes a viernes, de 5:30 a.m a 5:00 p.m. (PST)
Teléfono: +1 650 243 6335
Fax: 650 243 6388
info@prosigna.com

Seminario web en vivo – 16/5/23, 6pm: ¿Cómo pueden los subtipos moleculares guiar las decisiones terapéuticas?
Registro